Nls pharmaceutics announces positive safety data from in vitro cyp450 and transporter mediated drug-drug interaction studies of mazindol

Very low risk for drug-drug interactions (ddi) with mazindol er based upon results from in vitro metabolism and transporter studies demonstrated pharmacological differentiation versus currently available medications used to treat narcolepsy which can have significant ddi effects preventing co-administration or requiring dose adjustments zurich, switzerland / accesswire / june 14, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced positive data from five recently completed in vitro drug-drug interaction studies investigating the potential for ddi of mazindol, a triple monoamine reuptake inhibitor and partial orexin-2 agonist, as well as its hydrolyzed metabolite (m6).
NLSP Ratings Summary
NLSP Quant Ranking